{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for tyrosine in Relationship Comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT04223583: Phase 4 Interventional Completed Soft Tissue Sarcomas
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). Anlotibib is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Phase III development is underway for the treatment of thyroid cancer, gastric cancer, leiomyosarcoma; non-small cell lung cancer; synovial sarcoma; thyroid cancer etc.
Status:
Investigational
Source:
NCT03855852: Not Applicable Interventional Unknown status Bone Loss, Alveolar
(2019)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 2014
Source:
Dr. Cellapy SR Premium Solution by GM Holdings Co., Ltd
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:emupertinib [INN]
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
INN:enozertinib [INN]
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
NCT01868022: Phase 1 Interventional Completed Neoplasms
(2013)
Source URL:
Class:
CONCEPT
Status:
Investigational
Source:
INN:gozanertinib [INN]
Source URL:
Class:
CONCEPT
